Insulin, such as insulin isophane suspension and 70% human isophane suspension/30% human insulin injection, is available over the counter in 49 US states and the District of Columbia. Over-the-counter insulin is banned in Indiana.1 Reports suggest that some patients with diabetes who are uninsured or underinsured purchase Walmart-brand ReliOn (Novo Nordisk) insulin over the counter because it is considerably less expensive ($24.88 per 10-mL vial) than the Novolin (Novo Nordisk) and Humulin (Lilly) insulins sold over the counter at other pharmacies ($152-$163 per 10-mL vial).1-3 Information, however, is lacking to support these reports, and Walmart does not make public its sales data.1 We sought to obtain such information.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Goldstein JN, Patel RM, Bland K, Hicks LS. Frequency of Sale and Reasons for Purchase of Over-the-Counter Insulin in the United States. JAMA Intern Med. Published online February 18, 2019179(5):722–723. doi:10.1001/jamainternmed.2018.7279
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: